VHL and nonpapillary renal cell carcinoma: This suggests that the link between VHL mutation and ADFP expression in ccRCC could lead to adopting common therapeutic strategies, such as belzutifan or anthiangiogenic therapies (sunitinib, sorafenib, axitinib, or bevacizumab) [18,19,20].